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Abstract: Protein kinases catalyze the transfer of the γ-phosphoryl group of adenosine triphosphate (ATP) to the hydroxyl 
groups of protein side chains, and they play critical roles in regulating cellular signal transduction and other biochemical 
processes. They are attractive targets for today’s drug discovery and development, and many pharmaceutical companies are 
intensively developing various kinds of protein kinase inhibitors. A good example is the recent success with the Bcr-Abl 
tyrosine kinase inhibitor imatinib mesylate (Gleevec
TM) in the treatment of chronic myeloid leukemia. Though imatinib 
has dramatically improved the treatment of Bcr-Abl-positive chronic myeloid leukemia, resistance is often found in patients 
with advanced-stage disease. Several mechanisms have been proposed to explain this resistance, including point mutations 
within the Abl kinase domain, ampliﬁ  cation of the bcr-abl gene, overexpression of the corresponding mRNA, increased 
drug efﬂ  ux mediated by P-glycoprotein, and activation of the Src-family kinase (SFK) Lyn. We set out to develop a novel 
drug whose afﬁ  nity for Abl is higher than that of imatinib and whose speciﬁ  city in inhibiting Lyn is higher than that of 
SFK/Abl inhibitors such as dasatinib (Sprycel
TM) or bosutinib (SKI-606). Our work has led to the development of NS-187 
(INNO-406), a novel Abl/Lyn dual tyrosine kinase inhibitor with clinical prospects. To provide an overview of how a selec-
tive kinase inhibitor has been developed, this review presents chemical-modiﬁ  cation studies carried out with the guidance 
of molecular modeling, the structural basis for the high potency and selectivity of NS-187 based on the X-ray structure of 
the NS-187/Abl complex, and the biological proﬁ  ling of NS-187, including site-directed mutagenesis experiments.
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Introduction
Protein kinases play critical roles in regulating cellular signal transduction and other biochemical 
processes by catalyzing the transfer of the γ-phosphoryl group of adenosine triphosphate (ATP) to the 
hydroxyl groups of protein side chains. They are therefore attractive targets for today’s drug discovery 
and development, and many pharmaceutical companies are intensively developing kinase inhibitors 
that may have therapeutic value (Cohen, 2002). A good example is imatinib mesylate (Gleevec
TM), a 
speciﬁ  c inhibitor of breakpoint cluster region—Abelson tyrosine kinase (Bcr-Abl TK) (Buchdunger 
et al. 1996). Imatinib (Fig. 1) is efﬁ  cacious in the treatment of Philadelphia-chromosome—positive (Ph
+) 
leukemias such as chronic myeloid leukemia and Ph
+ acute lymphoblastic leukemia (Goldman et al. 
2003; Kimura et al. 2006). Philadelphia chromosome is a speciﬁ  c chromosomal abnormality resulting 
from a reciprocal translocation between chromosomes 9 and 22. This translocation fuses the c-abl 
proto-oncogene to bcr, leading to the production of a Bcr-Abl fusion protein that constitutively activates 
multiple signaling pathways. Because most patients with chronic myeloid leukemia have this abnormality, 
Bcr-Abl tyrosine kinase is a promising target for treating Ph
+ leukemias (Sawyers, 1999).
Within a few years of its introduction to the clinic, imatinib had dramatically altered the ﬁ  rst-line 
therapy for chronic myeloid leukemia, because most patients newly diagnosed with this disease in the 
chronic phase achieve durable responses when treated with imatinib (O’Brien et al. 2003). However, a 
small percentage of these patients, as well as most patients with advanced-phase chronic myeloid 
leukemia and Ph
+ acute lymphoblastic leukemia, relapse on imatinib therapy (Druker et al. 2002; 
Ottmann et al. 2002). Several mechanisms have been proposed to explain the cases of refractory disease 
and relapse, including point mutations within the Abl kinase domain, ampliﬁ  cation of the bcr-abl gene, 
overexpression of the corresponding mRNA (Gorre et al. 2001; Hofmann et al. 2002; Nardi et al. 2004; 94
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Deininger et al. 2005), increased drug efﬂ  ux from 
the target cells mediated by P-glycoprotein (P-gp) 
(Hegedus et al. 2002), and activation of Lyn, a 
Src-family protein kinase (SFK) (Donato et al. 
2003; Dai et al. 2004; Ptasznik et al. 2004).
To overcome imatinib resistance, higher doses 
of imatinib and combination therapy with other 
agents have been used, with some efﬁ  cacy. How-
ever, these strategies are limited in their application 
and effectiveness, especially for patients with muta-
tions in the Abl kinase domain (Cortes et al. 2003; 
Kantarjian et al. 2004; O’Brien et al. 2003b). There-
fore it is necessary to develop more-effective Abl 
TK inhibitors. Several SFK inhibitors from various 
chemical classes, including PD166326 (Wisniewski 
et al. 2002), SKI-606 (Golas et al. 2003), AP23464 
(O’Hare et al. 2004), and dasatinib (Sprycel
TM; 
formerly BMS-354825) (Shah et al. 2004) have been 
reported to be 100–300 times more effective than 
imatinib in blocking Bcr-Abl TK autophosphoryla-
tion, and this inhibition of autophosphorylation 
extends to point mutants of Bcr-Abl. However, while 
imatinib binds only to the inactive form of Bcr-Abl, 
these SFK/Abl inhibitors bind also to the active 
form, which shares considerable conformational 
similarity with the active forms of diverse kinases, 
including the SFKs (Nagar et al. 2003). This char-
acteristic of SFK/Abl inhibitors has some advantage 
with respect to Lyn kinase, because overexpression 
of Lyn may be associated with imatinib resistance 
(Donato et al. 2003; Dai et al. 2004; Ptasznik et al. 
2004). However, the effects of lower speciﬁ  city 
against SFKs are not yet fully understood, because 
these kinases play many important roles in vivo 
(Cary et al. 2002; Davis et al. 2003; Tanaka et al. 
1996; Touyz et al. 2001). In addition to these SFK/
Abl inhibitors, nilotinib (Tasigna
TM; formerly 
AMN107) has been developed as a novel Abl TK 
inhibitor. The in vitro inhibitory effect of nilotinib 
is 10–30 times greater than that of imatinib, but it 
is weaker than that of SFK/Abl inhibitors (Weisberg 
et al. 2005). Therefore, we set out to develop a drug 
whose afﬁ  nity for Abl is higher than that of imatinib 
and whose speciﬁ  city in inhibiting Lyn at clinically 
relevant concentrations without affecting the phos-
phorylation of other SFKs is greater than that of 
other SFK/Abl inhibitors.
Structural Analysis of Kinases
Protein kinases are attractive targets for drug 
discovery programs in many disease areas, and most 
kinase inhibitors under development act by directly 
competing with ATP at the ATP-binding site of 
kinases. However, there are more than 500 protein 
kinases (Manning et al. 2002), and the ATP-binding 
site is highly conserved among them. Selectivity is 
therefore an essential requirement for clinically 
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Figure 1. Chemical structures of Abl kinase inhibitors.95
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effective drugs targeted against protein kinases, and 
it is crucial to understand the structural characteris-
tics of the ATP-binding site. Because kinase 
inhibitors on the market and currently under 
development often lack a portion to interact with 
the phosphate-binding region of the ATP-binding 
site, the term “ligand-binding site” will be used 
hereinafter instead of the term “ATP-binding site”.
X-ray crystallography is a promising method 
for understanding the structural and physicochem-
ical characteristics of the ligand-binding sites of 
protein kinases, and we have closely examined the 
X-ray structure of the imatinib/Abl complex. We 
ﬁ  rst explored the ligand-binding site by using the 
3D atomic coordinates of Abl kinase (Nagar et al. 
2002), and then we calculated the surface proper-
ties of the binding site with a molecular modeling 
suite of MOE (Chemical Computing Group, Inc.). 
In Figure 2, the spheres indicate the predicted loca-
tions of an inhibitor’s atoms, and imatinib is shown 
for reference. The spheres are classiﬁ  ed as either 
hydrophilic (red) or hydrophobic (white) depend-
ing on whether or not they are in good hydrogen-
bonding locations. Green, blue, and red express 
the hydrophobic, hydrophilic, and exposed nature 
of the surface, respectively. A large part of the 
surface is shown in green, indicating the hydro-
phobic nature of the ligand-binding site of Abl.
The ﬁ  ve rings in imatinib were labeled A through 
E as shown in Figure 1, and the region of the bind-
ing site around the A and B rings is shown in 
Figure 2A. The positions and properties of the 
spheres in this region correspond well to those of 
the A and B rings of imatinib, and there is limited 
space for chemical modiﬁ  cation. There is also lim-
ited space around the C ring. In contrast, much space 
is available around the D ring, suggesting the fea-
sibility of an intensive program of chemical modi-
ﬁ  cation of this part of the molecule (Fig. 2B). The 
surface color of the part of the binding site adjacent 
to the terminal E ring of imatinib is blue, indicating 
that hydrogen-bonding interactions are probably 
important for the binding of the E ring (Fig. 2C).
Though X-ray crystallography is very helpful 
for understanding the structural and physicochem-
ical characteristics of ligand-binding sites, a suf-
ﬁ  cient number of X-ray crystallographic structures 
for exhaustive comparison of the binding sites of 
various kinases is not yet available. The only data 
generally available for any kinase is the amino acid 
sequence, and, accordingly, sequence similarity is 
widely used for classifying proteins and predicting 
biological activities (Hank et al. 1988; Hank et al. 
1991). However, it is difﬁ  cult to elucidate the 
structural characteristics of a ligand-binding site 
from the amino acid sequence alone.
We have developed a procedure to overcome this 
difﬁ  culty by using physicochemical descriptors of 
amino acids in conjunction with neural network 
modeling (Niwa, 2006). The physicochemical prop-
erties of amino acids were expressed by hydropho-
bic, steric and structural descriptors. Kinases are 
classiﬁ  ed into four major groups based on sequence 
similarity, AGC (PKA, PKG, and PKC families), 
CaMK (calcium/calmodulin-dependent protein 
kinases), CMGC (CDK, MAPK, GSK3, and CLK 
families), and TK (Hank et al. 1988). Abl kinase 
belongs to the TK group, so we aimed to elucidate 
which amino acids and which properties character-
ize the ligand-binding sites of TK, and to visualize 
the results by molecular graphics. TK ligand-bind-
ing sites are characterized by the branched nature 
of the side chains of the amino acids at positions 
313 and 315. The methyl group of the C ring of 
imatinib and similar tyrosine kinase inhibitors, 
known as the “ﬂ  ag methyl”, makes a large contribu-
tion to both their inhibitory activity and their selec-
tivity (Zimmermann et al. 1997). The C ring and the 
ﬂ  ag methyl are located close to the amino acids at 
positions 313 and 315. Another characteristic feature 
of the TK ligand-binding site is the short side chain 
of the amino acid at position 322, which forms a 
hydrogen bond with Tyr253 and helps to stabilize 
the inactive conformation of Bcr-Abl kinase. Based 
on the above results, we developed guidelines for 
the chemical modiﬁ  cation of Abl kinase ligands 
(Fig. 3). Though they are rather rough guidelines, 
they have helped us to understand the structural 
characteristics of the binding site of Abl kinase. In 
addition, they helped us to decide at the beginning 
of the project which kinds of chemical modiﬁ  cations 
were likely to be useful.
Chemical Modiﬁ  cation
To guide our chemical-modiﬁ  cation studies, we 
used the reported X-ray structure of the imatinib/
Abl complex (Nagar et al. 2002). When we closely 
examined the structure, we found a hydrophobic 
pocket formed by amino acids Ile293, Leu298, 
Leu354 and Val379 around the phenyl (D) ring of 
imatinib. To improve the antiproliferative activity of 
imatinib against Bcr-Abl-positive (Bcr-Abl
+) leuke-96
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mia cell lines, we focused on this hydrophobic pocket 
and introduced various hydrophobic substituents on 
the phenyl (D) ring (Asaki et al. 2006). We found that 
3-halogenated and 3-triﬂ  uoromethylated derivatives 
have signiﬁ  cantly increased inhibitory activity com-
pared to unsubstituted imatinib (Table 1).
To compensate for the increase in hydrophobicity 
caused by the introduction of the hydrophobic tri-
ﬂ  uoromethyl group in 5e, the distal pyridine (A) ring 
was selected for further modiﬁ  cation. In the crystal 
structure of the imatinib/Abl complex, Tyr253 is 
located very close to the A ring, and their interaction 
helps to stabilize the inactive form of the kinase. 
Therefore, a structural modiﬁ  cation that increases 
the bulk in this region would be expected to be unfa-
vorable. The pyridine ring was therefore replaced by 
the more hydrophilic pyrimidine ring. Pyrimidine 
derivative 9a displayed activity (IC50 = 4 nM) similar 
to the original pyridine derivative 5e, showing that 
pyrimidinyl substitution is compatible with the reten-
tion of inhibitory activity.
The crystal structure of the complex reveals 
that the piperazine moiety (E) of imatinib interacts 
with the carbonyl oxygen atoms of Ile360 and 
His361 through hydrogen bonding. Taking 
account of this important interaction, we replaced 
the piperazine moiety in 9a with other cyclic 
amines. The optically pure 3-(dimethylamino) 
pyrrolidine derivatives 9b and 9c, the 3-(dimeth
ylaminomethyl)pyrrolidine derivatives 9d and 9e, 
and the 3-(dimethylamino)azetidine derivative
9f, all of whose E-ring systems had the potential 
to function as piperazine isosteres, were synthe-
sized (Fig. 4). The pyrrolidine derivative 9c 
intensive 
modification to 
increase activity
hydrogen-bonding interactions
Tyr253
Asn322
Thr315
Ile313 careful 
modification
to keep 
selectivity
important for selectivity
Figure 3. Guidelines for chemical modiﬁ  cation.
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Figure 2. Structural properties of Abl kinase ligand-binding sites. Spheres indicate the probable locations of ligand atoms, and are classiﬁ  ed 
as either hydrophilic (red) or hydrophobic (white) depending on whether or not they are in good hydrogen-bonding locations. The surface 
colors green, blue, and red represent the hydrophobic, hydrophilic, and exposed nature of the surface, respectively.97
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exhibited excellent potency (IC50 = 4 nM), com-
parable to 9a. Compound 9b, the enantiomer of 
9c, and other pyridine derivatives (9d and 9e) had 
lower, though still excellent, antiproliferative 
activity (IC50 = 11, 11 and 9 nM, respectively). 
Azetidine 9f had lower potency still (IC50 = 17 nM). 
These results reveal that the antiproliferative activity 
is somewhat affected by the position of the terminal 
dimethylamino function. In other words, the differ-
ences in activity among these compounds may be 
attributed to subtle differences in the distance 
between the dimethylamino function and the car-
bonyl oxygen atoms of Ile360 and His361.
At the beginning of our project, the involvement 
of Lyn kinase in imatinib resistance was unknown. 
In 2003, Donato et al. reported the association of 
the overexpression of Lyn kinase with imatinib 
resistance (Donato et al. 2003; Dai et al. 2004; 
Ptasznik et al. 2004). Thereafter, we tried to develop 
Abl/Lyn dual inhibitors, and found that NS-187 (9b; 
INNO-406) and its derivatives also inhibit Lyn 
kinase. To investigate why this series of compounds 
act as dual Bcr-Abl/Lyn kinase inhibitors, we deter-
mined their inhibitory activities against Abl and Lyn 
kinases and studied their structure-activity relation-
ships (Horio et al. 2007). All compounds tested 
show more-potent inhibitory activity against Abl 
and Lyn than does imatinib (Table 1), and the 
inhibitory activities of 3-substituted benzamides 
against Abl and Lyn are highly correlated (r = 0.982 
when the activity is expressed as pIC50).
Judging from its overall characteristics, 
including its pharmacokinetics and toxicity as 
determined in animal studies, we selected 9b 
(NS-187) as a candidate for clinical development 
(Kimura et al. 2005; Asaki et al. 2006). NS-187 is 
Table 1. Inhibitory and antiproliferative activity of 3-substituted benzamide derivatives.
     
Compound X  R
1 R
2 IC50 (nM)
        K562 cells   U937 cells
a Abl
b Lyn
b
       (Bcr-Abl)
a    
imatinib CH  H    182  14,000    220  470
5a CH  F    63  8,000    35  120
5b CH  Cl    10  9,000    N.D.  N.D.
5c CH  Br    7  5,000    3.1  12
5d CH  I    10  6,000    N.D.  N.D.
5e CH  CF3   5  4,000   4.8  5.1
9a N  CF3   4  5,000   8.5  8.8
9b (NS-187)  N  CF3   11  10,000    11  26
9c
d N  CF3   4  9,000   3.4  12
9d
d N  CF3   11  20,000    N.D.  N.D.
9e
d N  CF3   9 100,000   7.6  32
9f 
d N  CF3   17 100,000 29  140
aIC50 represents the concentration of compound which inhibits cell proliferation by 50%.
bIC50 represents the concentration of compound which inhibits the kinase activity by 50%.
cND, not determined. 
dThe biological activity of the monohydrochloride salts was evaluated.
Adapted from Asaki et al. 2006 and Horio et al. 2006.
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now under investigation in a Phase I clinical trial 
with Ph
+ leukemia.
Structural Analysis of NS-187
X-ray structure of NS-187 bound 
to human Abl
We recently determined the X-ray structure of 
NS-187 bound to human Abl (Horio et al. 2007) 
shown in Figure 5B (Abl, blue; NS-187, yel-
low). For comparison, the X-ray structure of 
imatinib bound to Abl (Abl, cyan; imatinib, 
white) is shown in Figure 5A. Only the amino 
acids within 4 Å of NS-187 or imatinib are 
depicted for clarity. The two X-ray structures 
resemble each other very closely, with only 
slight differences in the positions of the ligands 
and the side chains and backbones of the 
kinases. Therefore it is clear that NS-187 and 
imatinib interact with Abl in very similar ways. 
This finding validates our use of the X-ray 
structure of the imatinib/Abl complex to guide 
our chemical-modification studies.
We checked whether our strategy for chemical 
modiﬁ  cation was appropriate by analyzing the 
X-ray structure of the NS-187/Abl complex 
(Fig. 5C). The triﬂ  uoromethyl (CF3) group is well 
placed to interact with the hydrophobic pocket 
formed by Ile293, Leu298, Leu354, and Val379, 
shown in magenta. Tyr253 is located close to the 
pyrimidine (A) ring, so that our use of a pyrimidine 
instead of a pyridine ring does not appear to alter 
the important role of Tyr253 in stabilizing the inac-
tive form of the kinase. Hydrogen-bonding interac-
tions are shown as broken white lines in Figure 5C, 
and it can be seen that the nitrogen atom of the 
dimethylamino group is well placed to interact with 
the carbonyl oxygen atoms of Ile360 and His361 
through hydrogen bonding. Our strategy for 
chemical modiﬁ  cation was thus validated.
Effects of the CF3 group of NS-187
The 3-substituents (R
1) on the D ring greatly 
enhance the inhibitory activity against both Abl and 
Lyn kinases (Table 1). To elucidate this effect, we 
quantitatively analyzed the effect of the 3-substituent 
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9a : R2 = 4-methylpiperazin-1-yl
9b : R2 = (3S)-3-(dimethylamino)pyrrolidin-1-yl
9c : R2 = (3R)-3-(dimethylamino)pyrrolidin-1-yl
9d : R2 = (3R)-3-(dimethylaminomethyl)pyrrolidin-1-yl
9e : R2 = (3S)-3-(dimethylaminomethyl)pyrrolidin-1-yl
9f : R2 = 3-(dimethylamino)azetidin-1-yl 
1-3a, 5a : R1 = F
1-3b, 5b : R1 = Cl
1-3c, 5c : R1 = Br
1-3d, 5d : R1 = I
1-3e, 5e : R1 = CF3
Figure 4. Chemical synthesis of 3-substituted benzamides. (A) Reagents and conditions for synthesis of 5a–e: (a) H2SO4, EtOH, reﬂ  ux;
(b) NBS, cat. (PhCO)2O2, CCl4, reﬂ  ux; (c) 1-methylpiperazine, K2CO3, THF, rt; (d) 1 N NaOH, reﬂ  ux, then aq. HCl; (e) SOCl2, reﬂ  ux; (f) 4, 
pyridine, rt. (B) Reagents and conditions for synthesis of 9a–f: (a) NaBrO3, NaHSO3, EtOAc; (b) (COCl)2, cat. DMF, CH2Cl2, rt; (c) 7, K2CO3, 
dioxane, rt; (d) cyclic amines, K2CO3, DMF, rt. Adapted from Asaki et al. 2006.99
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on the inhibitory activity of the compounds against 
Abl and Lyn kinases by using various physico-
chemical parameters of the 3-substituents. We 
found that the inhibitory activity is highly corre-
lated with the hydrophobic substituent parameter 
π (correlation coefﬁ  cient r = 0.958 for Abl and 
r = 0.977 for Lyn) (Horio et al. 2007). This means 
that the inhibitory effect increases with the hydro-
phobicity of the 3-substituent.
To understand this effect more clearly, we exam-
ined the molecular surfaces of Abl and Lyn kinases 
near the 3-substituent (Fig. 5D–F). It is apparent 
that there remains room to accommodate chemical 
modiﬁ  cation of the D ring in the hydrophobic pocket 
formed by the amino acids Ile293, Leu298, Leu354 
and Val379, shown in magenta in the X-ray structure 
of the imatinib/Abl complex (Fig. 5D). However, 
in the X-ray structure of the NS-187/Abl complex, 
the CF3 group occupies this hydrophobic pocket 
well (Fig. 5E). The modeled structure of the NS-
187/Lyn complex, which is based on the X-ray 
structure of the NS-187/Abl complex, is depicted 
in Figure 5F. Close to the 3-substituent there are 
four hydrophobic amino acids, Leu293, Leu298, 
Ile354 and Ile379, shown in magenta (Horio et al. 
2007). Although the identities of three of the four 
amino acids differ between Abl and Lyn, they are 
all hydrophobic amino acids. Therefore it is likely 
that the enhanced inhibitory activity of the modiﬁ  ed 
compounds against both Abl and Lyn can be 
explained by increased hydrophobic interactions. It 
is reasonable that the hydrophobic effect of the 
3-substituent, as expressed by π, significantly 
enhances the inhibitory activity.
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Figure 5. NS-187 and imatinib bound to Abl and Lyn. (A) and (B) are X-ray structures of imatinib/Abl and NS-187/Abl complexes, respectively. 
(C) shows important interactions between NS-187 and Abl. Comparison of the CF3 binding pocket in Abl and Lyn is shown in D–F. Meshes 
show the molecular surfaces of the kinases. The hydrophobic amino acids forming the hydrophobic pocket are shown in magenta. (D), (E) 
and (F) show the imatinib/Abl, NS-187/Abl, and NS-187/Lyn complexes, respectively. Adapted from Asaki et al. 2006 and Horio et al. 2007.100
Niwa et al
Analytical Chemistry Insights 2007:2 
The inhibitory activities of the compounds are 
also linearly correlated with the Sterimol parameter 
B1, which expresses the minimum width of the 3-
substituent (r = 0.988 for Abl and r = 0.991 for Lyn) 
(Horio et al. 2007); that is, the inhibitory effect 
increases with the size of the 3-substituent. Since 
the 3-substituent is located adjacent to the terminal 
dimethylaminopyrrolidine ring (E), it would be 
expected to hinder the rotation of the terminal ring. 
When we calculated the rotational barrier of the 
terminal ring by using the MMFF94x force ﬁ  eld 
with MOE, we indeed found a restricted rotation 
about the bond connecting the D and E rings of NS-
187 (Fig. 6). The CF3 group not only reduces the 
ﬂ  exibility of rotation of the terminal ring, but also 
helps NS-187 to adopt its bound (active) conforma-
tion (Kimura et al. 2006b). Because of the reduced 
loss of entropy upon binding, the inhibitory activity 
of the ligand would be expected to increase as the 
probability that it will adopt its active conformation 
increases. In addition, the reduced conformational 
ﬂ  exibility could reduce the probability of binding 
to other proteins, thereby reducing the probability 
of adverse side effects.
Though kinase inhibitors bearing a CF3 group 
are not rare, those with a CF3 group adjacent to 
another group are rare. The adjacent location of 
these groups is a very characteristic structural 
feature of NS-187. The increased hydrophobicity 
and reduced conformational ﬂ  exibility of NS-187 
relative to imatinib cooperate to enhance its 
inhibitory activity against both Abl and Lyn kinase 
and reduce the probability of binding to off-target 
proteins.
In Vitro Biological Activity of NS-187
NS-187 blocks wild-type Bcr-Abl
signaling
We compared the ability of NS-187 and imatinib 
to inhibit the phosphorylation of Bcr-Abl and 
other tyrosine kinases at the cellular level 
(Kimura et al. 2005). The IC50 values of NS-187 
against wild-type Bcr-Abl in human erythroleu-
kemia K562 cells and human embryonic kidney 
293T cells are 11 and 22 nM, respectively, while 
the corresponding values for imatinib are 280 
and 1200 nM. NS-187 is therefore 25 to 55 times 
more potent than imatinib in blocking Bcr-Abl 
autophosphorylation. NS-187 suppresses the 
phosphorylation of platelet-derived growth fac-
tor receptor (PDGFR) and c-Kit with a potency 
similar to that of imatinib. However, while the 
potency ranking for imatinib is PDGFR  c-Kit 
 Bcr-Abl, the potency ranking for NS-187 is 
Bcr-Abl  PDGFR  c-Kit, so that the specific-
ity of NS-187 for Bcr-Abl is greater than that 
of imatinib. Because inhibition of PDGFR or 
c-Kit could cause unpredictable adverse effects, 
specific inhibition of Bcr-Abl is desirable. 
Examination of the intracellular phosphoryla-
tion status of CrkL and ERK, downstream 
mediators of the effects of Bcr-Abl, revealed 
CF3 more flexible less flexible
rotation rotation
Imatinib NS-187
AB
Figure 6. Restricted ﬂ  exibility of NS-187 is shown by the rotational barrier about the bond connecting the D ring of imatinib or NS-187 and 
the terminal E ring. Conformers within 4 kcal/mol above the global minimum are depicted, and the stick models represent the active structures 
of imatinib (A) and NS-187 (B) bound to Abl kinase. Adapted from Kimura et al. 2006b.101
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that NS-187 inhibits the phosphorylation of 
these proteins in K562 cells at much lower con-
centrations than does imatinib. This inhibition 
of phosphorylation is also observed in the mouse 
ProB cell line BaF3 expressing wild-type Bcr-
Abl (BaF3/wt). Taken together, these findings 
indicate that NS-187 is much more potent and 
specific than imatinib in blocking the effects of 
Bcr-Abl.
Antiproliferative activity of NS-187 
against cells bearing wild-type
or mutated Bcr-Abl
More than 40 point mutations within the Abl kinase 
domain have been reported (Hochhaus and 
Rosee, 2004). NS-187 at physiologically obtainable 
concentrations inhibits the phosphorylation of Bcr-Abl 
bearing the M244V, G250E, Q252H, Y253F, E255K, 
E255V, F317L, M351T, E355G, F359V, H396P, or 
F486S mutations, but it does not inhibit the phos-
phorylation of the T315I mutant (Kimura et al. 2005). 
Against all mutants except T315I, NS-187 is at least 
ﬁ  ve times as potent as imatinib (Table 2).
NS-187 suppresses the growth of the Bcr-Abl
+ 
cell lines K562, KU812 and BaF3/wt much more 
potently than does imatinib, but neither drug affects 
the proliferation of the Bcr-Abl-negative cell line 
U937 (Kimura et al. 2005). NS-187 exhibits a con-
centration-dependent antiproliferative effect against 
BaF3 cell lines expressing the Bcr-Abl mutants 
M244V, G250E, Q252H, Y253F, E255K, M351T 
or H396P, but has no effect on BaF3 cells expressing 
the T315I mutant. Bcr-Abl/wt, Q252H and M351T 
are especially sensitive to NS-187. Imatinib, mean-
while, is much less active against all cell lines tested 
(Naito et al. 2006). NS-187 therefore potently inhib-
its both the intracellular phosphorylation of most 
mutated Bcr-Abl kinases and the proliferation of 
cells expressing these kinases.
Mechanisms of NS-187-mediated cell 
death in Bcr-Abl
+ leukemic cells
NS-187 augments the activity of pro-apoptotic 
Bcl-2 homology domain 3 (BH3)-only proteins 
and induces apoptosis in Bcr-Abl
+ leukemic cells, 
as evidenced by DNA fragmentation, caspase-3 
activation, and the loss of mitochondrial-outer-
membrane permeabilization (Kuroda et al. 2007). 
ABT-737, an inhibitor of Bcl-2 and Bcl-XL, 
enhances the apoptosis induced by NS-187, even 
in cells with mutated Bcr-Abl that are less sensi-
tive to NS-187, suggesting that Bcl-2-family-
regulated, intrinsic apoptosis occurs through 
caspase activation. Even in the presence of the 
pan-caspase inhibitor zVAD-fmk, NS-187 still 
induces apoptosis in some cells, indicating the 
additional involvement of NS-187 in a caspase-
independent apoptotic pathway. The observation 
of an increased number of cells showing the hall-
marks of autophagy suggests that autophagy 
participates in the response against Bcr-Abl 
blockade. Inhibition of autophagy by chloroquine 
signiﬁ  cantly enhances NS-187-induced cell death. 
These results may be useful in the design of a 
rational therapeutic approach for efficiently 
eradicating Bcr-Abl
+ leukemic cells.
Inhibition of phosphorylated Abl by 
NS-187
Imatinib inhibits the kinase activity of the Tyr393-
unphosphorylated form of the Abl kinase domain 
with an IC50 value of 35 nM but has little effect on 
the phosphorylated form. In contrast, NS-187 
effectively inhibits the kinase activity of both 
Tyr393-phosphorylated and Tyr393-unphosphory-
lated forms of Abl with respective IC50 values of 
72 nM and 30 nM, suggesting that NS-187 may 
have sufﬁ  ciently high afﬁ  nity for Bcr-Abl to enable 
it to bind even to an unfavourable conformation of 
the kinase (Naito et al. 2006).
Table 2. Effect of NS-187 and imatinib on in vitro phos-
phorylation of puriﬁ  ed wild-type and point-mutated Abl 
kinase domains.
 IC50  (nM)
Abl kinase  NS-187  imatinib
Wild type  72   1,100 
M244V 240    3,500 
G250E 160    2,000 
Q252H 410    2,100 
Y253F 81    1,500 
E255K 540    5,800 
E255V 1,400    >10,000 
T315I >10,000    >10,000 
F317L 760    1,900 
M351T 150    3,900 
E355G 580    7,100 
E359V 1,300    >10,000 
H396P 95    1,400 
F486S 470    9,500 
Adapted from Kimura et al. 2005.102
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Selectivity of NS-187 for Abl
A panel of 79 tyrosine kinases, including the 
five Src-family proteins Blk, Src, Fyn, Lyn and 
Yes, was assayed in the presence and absence 
of NS-187 or imatinib (Kimura et al. 2005). 
Concentrations of 0.1 µM NS-187 and 10 µM 
imatinib were used because these concentrations 
give equal inhibition of Abl. At 0.1 µM, NS-187 
strongly inhibits only three of the 79 tyrosine 
kinases, that is, Abl, Arg and Lyn (Fyn is less 
strongly inhibited). At this concentration, NS-
187 does not inhibit PDGFRα, PDGFRβ, Blk, 
Src or Yes. In contrast, 10 µM imatinib inhibits 
nine tyrosine kinases, that is, Abl, Arg, Blk, Flt3, 
Fyn, Lyn, PDGFRα, PDGFRβ and p70S6K. 
NS-187 therefore inhibits Abl more selectively 
than does imatinib. The IC50 values of NS-187 
for Abl, Src and Lyn are 5.8, 1700 and 19 nM, 
respectively, while those of imatinib are 106, 
10,000 and 352 nM, respectively. These ﬁ  ndings 
suggest that NS-187 acts as an Abl/Lyn dual 
inhibitor while otherwise remaining highly 
speciﬁ  c.
In Vivo Anti-Tumor Activity of NS-187
Activity of NS-187 in mouse tumor 
models
The ability of NS-187 to suppress tumor growth was 
tested in two murine tumor models (Kimura et al. 
2005). In one model, Balb/c-nu/nu mice were 
injected subcutaneously with KU812 cells on Day 0 
and given NS-187 or imatinib orally twice a day 
from Day 7 to Day 17. At 20 mg/kg/day, imatinib 
inhibits tumor growth slightly, while at 200 mg/kg/
day, it inhibits tumor growth almost completely. 
NS-187, meanwhile, signiﬁ  cantly inhibits tumor 
growth at only 0.2 mg/kg/day, while at 20 mg/kg/day 
it completely inhibits tumor growth without adverse 
effects. When mice were treated with NS-187 at 0.2 
or 20 mg/kg/day, the estimated Cmax was 4 or 
400 nM, respectively, comparable to the concentra-
tions at which the in vitro effects of NS-187 are 
obtained. NS-187 is therefore at least 10-fold more 
potent than imatinib in vivo with complete inhibition 
of tumor growth as the end-point and at least 100-
fold more potent with partial inhibition as the end-
point. NS-187 was well tolerated by the mice.
In the other model, Balb/c-nu/nu mice intrave-
nously injected with BaF3/wt cells were given 
NS-187 or imatinib orally for 11 days starting on 
Day 1. All seven untreated mice had died by Day 
23 due to leukemic cell expansion, while all mice 
treated with 400 mg/kg/day imatinib had died by 
Day 25. NS-187, in contrast, signiﬁ  cantly pro-
longed the survival of the mice in a dose-dependent 
manner compared with untreated mice.
To investigate the efﬁ  cacy of NS-187 in a 
mouse model of leukemia, we tested its ability to 
block the growth of BaF3 cells expressing mutated 
Bcr-Abl in Balb/c-nu/nu mice (Naito et al. 2006). 
Mice bearing BaF3 cells expressing M244V, 
G250E, Q252H, Y253F, E255K, T315I, M351T 
or H396P were treated with NS-187 or imatinib. 
Mice bearing BaF3 cells expressing wild-type 
Bcr-Abl or any mutant form of Bcr-Abl except 
T315I show signiﬁ  cant prolongation of survival 
when they receive NS-187 at a dosage of 200 
mg/kg/day, without any apparent signs of toxicity 
(Fig. 7). These in vivo results are consistent with 
the in vitro results. Imatinib, even at a dosage of 
400 mg/kg/day, is much less effective. NS-187 
results in the highest observed percentage increase 
in mean survival in mice bearing BaF3 cells 
expressing wild-type Bcr-Abl, Q252H or M351T, 
in good agreement with the in vitro results. More-
over, the rank-order of the IC50 values for cell 
growth inhibition is inversely correlated with the 
percentage increase in the mean survival of mice 
treated with NS-187. Thus, the efﬁ  cacy of NS-187 
in the mouse leukemia model mirrors its in vitro 
activity, a result which suggests that NS-187 will 
be clinically effective.
Activity of NS-187 against central 
nervous system leukemia
Because the penetration of imatinib into the 
central nervous system (CNS) is poor, the CNS 
can become a sanctuary site of relapse in 
patients on prolonged imatinib therapy. P-gp 
plays an important role in limiting the distribu-
tion of imatinib to the CNS, and it is well known 
that imatinib is a substrate for P-gp. Our pre-
liminary pharmacokinetic study (Yokota et al. 
2007) showed that the intracranial concentration 
of NS-187 is only 10% of its serum concentra-
tion, suggesting the involvement of P-gp. How-
ever, even though NS-187 is a substrate for 
P-gp, it still inhibits the proliferation of leuke-
mic cells in the brain, whereas imatinib does 
not. NS-187 significantly prolongs the survival 
of mice in a dose-dependent manner in two CNS 103
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leukemia murine models compared with ima-
tinib. Furthermore, cyclosporine A, a P-gp 
inhibitor, augments the in vivo activity of NS-
187 against CNS Ph
+ leukemia, as shown by 
whole-brain fluorescence imaging (Fig. 8A–D) 
and survival curves (Fig. 8E and F). These find-
ings indicate that NS-187 is a promising agent 
for the treatment of CNS Ph
+ leukemia.
Phase I clinical study of NS-187 
(INNO-406)
A phase I study of NS-187 (INNO-406) in 21 
patients with Ph
+ leukemia who were resistant to 
or intolerant of imatinib is in progress (Kantarjian 
et al. 2007).
Summary and Conclusions
Using X-ray crystallographic information and com-
puter modeling, we have developed a highly potent 
and selective Abl/Lyn dual tyrosine kinase inhibitor, 
NS-187 (INNO-406). Its characteristic structural 
features are a triﬂ  uoromethyl group on the D ring that 
occupies a hydrophobic pocket of the Abl ligand-bind-
ing site and an adjacent dimethylaminopyrrolidine E 
ring whose rotation is restricted by the triﬂ  uoromethyl 
group. These features not only enhance inhibitory 
activity against Abl but also increase selectivity by 
reducing binding to off-target proteins. NS-187 has 
higher potency in inhibiting Abl than does imatinib 
and higher selectivity in inhibiting Lyn than do other 
SFK/Abl inhibitors. NS-187 is less sensitive to point 
mutations in the Abl kinase domain than are other 
Figure 7. In vivo activity of NS-187 in an imatinib-resistant mouse leukemia model. (A–H) BALB/cA-nu mice were intravenously injected 
with Ba/F3 cells expressing the indicated mutant forms of Bcr-Abl on day 1. The mice were orally administered twice daily with NS-187 
(green), imatinib (blue) or vehicle (red) from day 2 through day 12. The survival of the mice was assessed by the method of Kaplan and 
Meier. Adapted from Naito et al. 2006.
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inhibitors such as imatinib, while maintaining a high 
selectivity for Abl and Lyn. NS-187 may be effective 
in the treatment of chronic myeloid leukemia with 
possible application to CNS leukemia and it may also 
be less liable to cause unfavorable side effects than 
are therapeutic agents that target multiple kinases, such 
as SFK inhibitors.
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Figure 8. Combined effect of CsA and NS-187 in an in vivo CNS leukemia model. BALB/cA Jcl-nu mice were inoculated into the right 
cerebral ventricle with 5 × 10
4 BaF3/wt bcr-abl
GFP (A–E) or BaF3/bcr-abl/M351T (F) cells on day 0. Mice were orally administered vehicle 
(A, black line in E and F), 50 mg/kg CsA (B, blue line in E and F), 60 mg/kg/day NS-187 (C, magenta line in E and F), or a combination 
of CsA and NS-187 (D, red line in E and F) from day 5 to day 15. Brains from each group were taken on day 17. Adapted from Yokota 
et al. 2007.
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